Complex neurological diseases include Alzheimer’s and Parkinson’s disease, neuromuscular disorders such as amyotrophic lateral sclerosis (ALS), and psychiatric conditions including depressive disorders and schizophrenia, which are all the result of multifactorial interactions.
It is only recently through next-generation sequencing (NGS) studies that the full genomic complexity of neurological diseases is being revealed. The interplay between heritable and nonheritable mutations, epigenetics, and other factors requires NGS-level analyses to increase our understanding. Illumina has the array and NGS tools needed to make genomic neuroscience research possible.
Infinium PsychArray BeadChip: This array enables researchers to evaluate genetic variants associated with common psychiatric disorders.
Kailos TargetRich PGxComplete: This enrichment-based targeted sequencing research panel covers 43 genes associated with responses to ~100 medications.
Kailos Blue Analytics: These solutions provide sequencing quality assessment, alignment, and variant calling in output formats suitable for use with a variety of reporting solutions.
Researchers in the neurogenomics community contributed content for the Neuro Consortium Array, a high-density array featuring over 180,000 markers associated with common neurodegenerative diseases. The array offers a high-throughput genotyping solution for fine mapping and replication of disease-associated variants.Learn More
Through this consortium, scientists selected content for the TruSeq Neurodegeneration Panel based on recent scientific findings. The TruSeq Neurodegeneration Panel offers a high-throughput approach to identifying and validating variants associated with risk for multiple neurodegenerative diseases.Learn More